If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Norway's committee recommends dropping AstraZeneca, J&J jabs

Mon, 10th May 2021 12:08

(Alliance News) - An expert committee set up by Norway's government to evaluate AstraZeneca PLC's and Johnson & Johnson's Covid-19 vaccines said on Monday that both should be abandoned over risks of rare but serious side effects.

In order to avoid a slowdown of the vaccine rollout the committee recommended that the two jabs should be made available for people on a voluntary basis.

The committee's head Lars Vorland said they did "not recommend the use of adenoviral vector vaccines in the national immunisation programme", as he handed in their report.

"This is of course because of the serious side effects" observed in a small proportion of people who have been injected with these vaccines, Vorland added. 

Health Minister Bent Hoie has not yet made the government's position on the use of the vaccines known. 

From the 134,000 injections of AstraZeneca's vaccine administered in Norway up until mid-March, five cases of severe thrombosis – three of them fatal – were reported in relatively young and previously healthy people. Another vaccine recipient died of a brain haemorrhage.

Norway suspended AstraZeneca's vaccine on March 11 while its rare but potentially serious side effects were studied in more detail. 

On April 15, Norwegian health authorities recommended dropping the jab from the Anglo-Swedish drugmaker, but the government chose to first set up a committee of experts to examine the risks associated with the AstraZeneca and Johnson & Johnson vaccines – which are both based on the same adenovirus technology.

The European Medicines Agency and the World Health Organization both recommend continued use of the vaccines, arguing that the benefits far outweigh  the associated risks.

US drugmaker Johnson & Johnson's vaccine has not yet been deployed in the country, but rare cases of thrombosis have been reported in the US. 

Neighbouring Denmark is the only country in Europe that has officially dropped AstraZeneca and Johnson & Johnson's vaccines, but many have restricted the use of AstraZeneca's to certain age groups.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
Today 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...

Today 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4% *

Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...

Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...

Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.